Ethanol Infusion in the Vein of Marshall for Persistent Atrial Fibrillation Ablation: Evidence From Randomized Controlled Trials
Journal of Cardiovascular Electrophysiology · 2025
DOI: 10.1111/jce.70090 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von Carolina Saleiro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pacing & Electrophysiology Unit, Cardiology Department, Coimbra's Hospital and University Center, Coimbra, Portugal. Hauptthemen laut MEDLINE: Atrial Fibrillation, Ethanol, Catheter Ablation, Pulmonary Veins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation (CA) for atrial fibrillation (AF), yet outcomes remain suboptimal in persistent AF patients. Ethanol infusion in the vein of Marshal (VoM), an embryological remnant implicated in AF pathogenesis, may enhance ablation efficacy.
Objective
To evaluate the effectiveness of VoM ethanol infusion in patients with persistent AF.
Methods
We conducted a systematic review and meta‐analysis of randomized controlled trials (RCT) comparing CA with versus without VoM ethanol infusion in patients undergoing first‐time ablation of persistent AF. The primary endpoint was freedom from any atrial arrhythmia in a 12‐month follow‐up.
Results
Four RCTs including 1045 patients were analyzed (VoM + CA—535 patients vs. CA alone—510 patients). Ethanol infusion in the VoM significantly increased freedom from atrial arrhythmias (RR 1.21; 95% CI 1.010–1.32; p < 0.0001, NNT 10) and reduced the need of a repeat procedure (RR 0.63; 95% CI 0.45–0.87; p = 0.005). Mitral isthmus (MI) block was more frequently achieved in the VoM group (RR 1.30; 95% CI 1.03–1.65; p = 0.03) There was no significant difference in the rate of major complications (2.8% vs. 3.5%, RR 0.72; 95% CI 0.37–1.43; p = 0.35, NNH 138), although overall complications were more frequent in the VoM ethanol infusion group (RR 2.25; 95% CI 1.08–4.70; p = 0.03).
Conclusion
When added to CA, ethanol infusion in the VoM improves freedom from arrhythmia without increasing the risk of major complications. These findings may support its integration into ablation strategies for persistent AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pacing & Electrophysiology Unit, Cardiology Department, Coimbra's Hospital and University Center, Coimbra, Portugal.
- Cardiology Department, Hospital da Luz Arrábida, Vila Nova de Gaia, Portugal.
- ICBR, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
- Houston Methodist DeBakey Heart and Vascular Center and Research Institute, Houston, Texas, USA.
ORCID-Profile: Carolina Saleiro, Sérgio Barra, Miguel Valderrábano, Pedro A Sousa
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Saleiro, C., Barra, S., Oliveiros, B., Alves, P., Ferreira, J., António, N., Elvas, L., Gonçalves, L., Valderrábano, M., & Sousa, P. A. (2025). Ethanol Infusion in the Vein of Marshall for Persistent Atrial Fibrillation Ablation: Evidence From Randomized Controlled Trials. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70090
Vancouver
Saleiro C, Barra S, Oliveiros B, Alves P, Ferreira J, António N, et al. Ethanol Infusion in the Vein of Marshall for Persistent Atrial Fibrillation Ablation: Evidence From Randomized Controlled Trials. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.70090
BibTeX
@article{Saleiro2025,
author = {Saleiro, Carolina and Barra, Sérgio and Oliveiros, Bárbara and Alves, Patrícia and Ferreira, João and António, Natália and Elvas, Luís and Gonçalves, Lino and Valderrábano, Miguel and Sousa, Pedro A},
title = {Ethanol Infusion in the Vein of Marshall for Persistent Atrial Fibrillation Ablation: Evidence From Randomized Controlled Trials},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2025},
doi = {10.1111/jce.70090}
}
EUVIMED